Insufficient antiretroviral therapy in pregnancy: Missed opportunities for prevention of mother-to-child transmission of HIV in Europe

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 895-903

  Bailey, Heather ^a   Townsend, Claire ^a   Cortina Borja, Mario ^a   Thorne, Claire ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPARTUM CARE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREND STUDY; VERTICAL TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 80052940731     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1849     Document Type: Article

References (41)

1. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-299.
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
3. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20:1419-1427.
4. National Study of HIV in Pregnancy and Childhood, NHS Audit Information Analysis Unit, Children's HIV Association. Perinatal transmission of HIV in England 2002-2005. London, UK: Audit Information and Analysis Unit for London, Kent, Surrey and Sussex, Essex, Beds & Herts 2007.
5. Deblonde J, Claeys P, Temmerman M. Antenatal HIV screening in Europe: a review of policies. Eur J Public Health 2007; 17:414-418. (Pubitemid 350034004)
6. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG 2008; 115:1078-1086.
7. Keiser O, Gayet-Ageron A, Rudin C, et al. Antiretroviral treatment during pregnancy. AIDS 2008; 22:2323-2330.
8. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (Updated 24 May 2010. Accessed 29 June 2011.) Available from http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
9. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9:452-502.
10. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026. (Pubitemid 46684333)
11. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern? Drug Saf 2007; 30:203-213.
12. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337-2339. (Pubitemid 39620231)
13. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380-387.
14. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-465.
15. Jasseron C, Mandelbrot L, Tubiana R, et al. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women? AIDS 2008; 22:1503-1511.
16. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494. (Pubitemid 34456340)
17. European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656.
18. Landes M, Newell ML, Barlow P, et al. Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe. HIV Med 2008; 9:526-534.
19. von Linstow ML, Rosenfeldt V, Lebech AM, et al. Prevention of mother-to-child transmission of HIV in Denmark, 1994-2008. HIV Med 2010; 11:448-456.
20. World Health Organisation. Antiretroviral drugs for treating pregnant women and preventing HIV infection in their infants: Recommendations for a public health approach. 2010 version. Geneva, Switzerland: World Health Organisation; 2010.
21. European Collaborative Study. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11:368-378.
22. Royal College of Obstetricians and Gynaecologists. Medical terms explained. (Updated April 2011. Accessed July 2011.) Available from http://www.rcog.org.uk/womens-health/patient-information/medical-terms-explained
23. US Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
24. Rabe-Hesketh S, Skrondal A, Pickles A. Reliable estimation of generalised linear mixed models using adaptive quadrature. Stata J 2002; 2:1-21.
25. Mayaux MJ, Teglas JP, Blanche S, the French Pediatric HIV Infection Study Group. Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr 2003; 34:338-343. (Pubitemid 37377370)
26. Vandermaelen A, Barlow P, Manigart Y, et al. Optimal management of HIV-infected women during pregnancy and delivery: an audit of compliance with recommendations. J Womens Health (Larchmt) 2009; 18:1881-1887.
27. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis 1999; 179:52-58. (Pubitemid 29028338)
28. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377-1385.
29. European Collaborative Study, the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-2920.
30. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-87.
31. Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9:6-13.
32. HIV/AIDS Programme WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in their infants: Recommendations for a public health approach. 2010 version. Geneva, Switzerland: World Health Organisation; 2010.
33. Giraudon I, Forde J, Maguire H, Arnold J, Permalloo N. Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. Eurosurveillance 2009; 14:8-12.
34. Department of Health UK. Definitions of health literacy. (Updated 10 August 2009. Accessed 10 March 2010.) Available from http://www dh gov uk/en/Publichealth/Healthimprovement/Healthliteracy/DH-095381
35. Turner BJ, Cunningham WE, Duan N, et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000; 160:2614-2622.
36. Samet JH, Freedberg KA, Stein MD, et al. Trillion virion delay; time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998; 158:734-740. (Pubitemid 28204658)
37. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 2008; 168:1181-1187. (Pubitemid 351831401)
38. Peters V, Liu KL, Dominguez K, et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, Pediatric Spectrum of HIV Disease Cohort. Pediatrics 2003; 111:1186-1191.
39. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health 2004; 94:1147-1151. (Pubitemid 38857315)
40. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96-103.
41. Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008; 16: CD006318.